Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04158700
Title A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | FRA | ESP


No variant requirements are available.